ERBB2 and gastric cancer: To treat GC in a palliative setting, FDA has approved two new monoclonal antibodies: ramucirumab, which attacks VEGFR 2 (vascular endothelial growth factor receptor 2), and tratuzumab attacks HER2 (human epidermal growth factor receptor 2) [5].